The US Bankruptcy Court gave an order approving the sale of the certain assets of Genocea Biosciences, Inc. on September 21, 2022. The debtor has been authorized to sell its certain assets to Harpy Holdings, LLC for a purchase price of $2 million in cash, pursuant to the asset purchase agreement, dated August 2, 2022. The debtor's assets include intellectual property related to the ATLAS platform, including a portfolio of patents and trademarks, research and clinical trial data, research materials, and software URLs and related equipment.

The buyer shall make a cash deposit of $0.20 million to the escrow agent and the balance will be paid on closing. The buyer would be entitled to a break-up fee and expense reimbursement of $0.10 million in case of termination of the asset purchase agreement.